{"transactions":[{"id":1385074,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":679163,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":60554},"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385073,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":15001312,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1337513},"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385072,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":545454,"price":11,"value":5999994.0,"ownership":{"direct":false,"nature":"By AH Bio Fund IV, L.P., as nominee"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by AH Bio Fund IV, L.P. (\"AH Bio IV\"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP (collectively, the \"AH Bio Fund IV Entities\"). AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\"), the general partner of AH Bio IV, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio IV, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio IV and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":545454,"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385071,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":181818,"price":11,"value":1999998.0,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":1579885,"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385070,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1398067,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":1398067,"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}}]}